Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2019 | Implications of apoptotic MSCs inducing PG-E2

Francesco Dazzi • 14 Jun 2019
EHA 2019
General

Francesco Dazzi, MD, PhD, King’s College London, London, UK, explains that the therapeutic effect of the mesenchymal stromal cells (MSCs) includes reprogramming monocytes to release the prostaglandin PG-E2. This interview took place at the 24th Congress of the European Hematology Association (EHA) 2019, held in Amsterdam, Netherlands.

More from Francesco Dazzi

3:35
Challenges with implementing mesenchymal stem cells into practice
Francesco Dazzi • 4 Sep 2020
1:55
Mesenchymal stromal cells in 2020
Francesco Dazzi • 3 Sep 2020
2:07
Cell death pathways in MSC
Francesco Dazzi • 14 Jun 2019
1:18
Mesenchymal stromal cells: a mechanistic overview
Francesco Dazzi • 15 Jun 2019

Related Videos

4:33
The EBMT Patient Advocacy Committee: Patient, Family and Donor Day at EBMT 2024
Natacha Bolaños • 16 Apr 2024
2:55
Distinguishing late-onset neutropenia from classical primary neutropenia
Carlo Dufour • 15 Apr 2024
2:39
The MAGIC algorithm probability to predict outcomes of GvHD in the GI tract
James Ferrara • 16 Apr 2024
2:25
The EBMT Trainee Committee: in-person trainee day at EBMT 2024 and upcoming initiatives
Claire Horgan • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals